Evolve DD — 2026-05-04

Type: Deep Evolution Round

Date: 2026-05-04

Stocks Updated: Japan Steel Works (5631.T), Organo Corporation (6368.T), ANYCOLOR (5032.T)

Selection Criteria: All three are HIGH conviction. JSW and Organo have FY2025 earnings due May 13 — critical pre-earnings update. ANYCOLOR is the most stale HIGH conviction stock (data_date 2026-04-12) with FY2026 earnings May 14.

1. Japan Steel Works (5631.T) — HOLD

Theme: Nuclear | Layer: Materials / Forgings | Conviction: HIGH

What Changed

KEY CORRECTION: FY2025 earnings date is May 13 2026, not May 8.

Thesis Update

EPR-2 (EDF France, up to 6 units) confirmed as active supply chain — forging work began December 2024. JSW M&E absorption merger completed April 1 2026, eliminating subsidiary overhead and accelerating nuclear capex decisions. Nuclear order intake Q3 cumulative +19.4% YoY. Nuclear materials & engineering division orders: +45% YoY (H1 FY2025).

BWRX-300 nuance (corrected): BWXT (Canada) won the Darlington Unit 1 RPV contract (January 2025). JSW is NOT the RPV supplier for the first Canadian BWRX-300 unit. JSW's BWRX-300 role is in non-RPV forgings (steam generators, rotor shafts) and as a strong candidate for the Tennessee/Alabama 10-unit program ($40B, announced March 19 2026 at Trump-Takaichi summit). BWXT capacity is physically insufficient for all 10 Tennessee/Alabama units.

US-Japan nuclear geopolitics (March 2026): ~$40B GE Vernova/Hitachi BWRX-300 (Tennessee: Clinch River, Alabama: ~3GW total, ~10 units); Westinghouse strategic deal $80-100B. Both explicitly aim to "incorporate qualified Japanese suppliers." JSW is the natural candidate for large forging supply at scale.

FY2025 Q3 cumulative: Revenue ¥201.1B (+16.4%), OP ¥17.5B (+2.9%), tracking to full-year guidance of ¥290B revenue / ¥24.5B OP. FCF remains negative in heavy capex phase; JGP2028 targets positive FCF from FY2027 onward. All 5 analysts: Buy. Average PT ¥11,080–11,560 (~19-25% upside from ¥9,283).

Thesis breaks if: Tennessee/Alabama BWRX-300 program is cancelled or JSW not selected; FCF still negative after FY2028 end of capex cycle; EPR-2 France delayed by budget/political issues.

Supply Chain (Updated)

Risk Flags

• None triggered on valuation guardrails. PB 3.35x not extreme for a capital-goods growth company.
• PE ~34.6x on negative FCF is expensive — risk acknowledged, justified by FY2027-2029 earnings ramp as ¥300B+ backlog converts.
• BWRX-300 RPV nuance: thesis was slightly overstated. Corrected — BWXT won the first Canadian unit's RPV specifically. JSW moat remains in non-RPV forgings and multi-unit scale.

2. Organo Corporation (6368.T) — HOLD ⚠️ PB Risk Flag

Theme: Nuclear | Layer: Nuclear Operations / Water | Conviction: HIGH

What Changed

Thesis Update

KK-6 ABWR (1,356 MW) commercially restarted April 16, 2026 — the largest single BWR restart since Fukushima, and a direct Organo revenue event. All BWR condensate demineralizer vessels use Organo's IFD technology (monopoly since 1970); each restart → Organo maintenance contracts.

FY2025 actuals confirmed (March 31 year-end): Revenue ¥163.3B (+8.6%), OP ¥31.1B (+38%), NI ¥24.2B (+39.5%). Dividend raised twice to ¥190/share (from initial ¥160). FY2026 guidance also raised twice to OP ¥36B (+15.7%). Q3 FY2026 cumulative (9 months): Revenue ¥127.7B (+10.4%), OP ¥26.1B (+32.2%).

Semiconductor UPW expansion confirmed: TSMC JASM Phase 2 groundbreaking October 2025, operations targeted late 2027. Organo is natural repeat vendor. Rapidus Chitose confirmed as water treatment customer (Organo cited explicitly in reporting). TSMC Arizona: Organo's Arizona office already serving TSMC — same growth trajectory as Asia.

TSMC Q1 2026: Revenue +41%, net +58%, FY2026 guidance raised to 30%+ growth — Organo's anchor semiconductor customer at peak momentum.

Thesis breaks if: NRA halts additional BWR restarts; AI semiconductor capex cycle reverses materially; Rapidus Chitose project cancelled or delayed beyond 2028.

Supply Chain (Updated)

Risk Flags

⚠️ PB GUARDRAIL TRIGGERED — HARD FLAG: PB 5.73x exceeds the all-time historical maximum of 3.78x (IRBank 15-year data). This is not merely above the 80th percentile — the current multiple is above every data point in the last 15 years. The stock has risen ~10x in five years.

Assessment: The PB re-rating reflects Organo's transformation from a utility-services company to a secular-growth compounder (nuclear + AI semiconductor). A Simply Wall St DCF model suggests ~29-40% undervaluation on cash flow basis. However, any execution stumble risks de-rating back toward 2-3x PB (50%+ downside). Position sizing should reflect this tail risk. Monitoring trigger: if PB exceeds 7x without a corresponding EPS upgrade in May 13 earnings, trim.

OP Growth Deceleration Watch: FY2025 OP +38% → FY2026 guided +15.7%. Deceleration is visible. Management initially guided flat OP growth for FY2026 — raises came from material cost savings, not structural margin expansion. Not a peak-earnings trap yet, but warrants monitoring.

Offsetting positives: KK-7 restart delayed to 2029-2030 (bearish) and Hamaoka suspended (bearish) are offset by KK-6 restart (April 2026, immediate revenue), JASM Phase 2 (2027 revenue), and Arizona expansion pipeline.

3. ANYCOLOR (5032.T) — HOLD (Potential UPGRADE pending May 14)

Theme: VTuber | Layer: VTuber Agency / IP Platform | Conviction: HIGH

What Changed

Thesis Update

The stock has derated 55% (¥6,790 → ¥3,075) over 12 months, collapsing PE from ~20x to 10.24x — the stock is near its 52-week low. Meanwhile revenue is growing at 28-30% in FY2026 (following +34% in FY2025), and 9-month cumulative revenue of ¥42.0B already exceeds FY2025 full-year (¥42.88B). At 10x PE with 74% ROE and 28-30% revenue growth, this appears to be deep value territory. Three analysts have consensus PT of ¥6,248-6,780, implying ~100%+ upside.

Key drivers behind derating:

1. EN branch talent attrition (2025): ~7 graduations, roster ~28 (from ~45+ peak). However, total talent count is 172 (+7 YoY) — JP/KR additions exceeded EN losses.

2. Q3 FY2026 guidance cut: Inventory write-down/evaluation losses on merchandise drove operating profit guidance cut. Revenue guidance was simultaneously RAISED. Assessment: one-time cost of goods issue, not business model deterioration.

3. Cover Corp growing faster on revenue (~50% Q1 FY2026 vs ANYCOLOR ~30%).

New developments:

• BY THE BEAT × Universal Music Japan: 4-member EN unit signed with Virgin Music Japan. Double Vision single released March 29, 2026. Major label debut targeted 2027 — first VTuber unit on a major Western label track. Opens new music IP revenue stream.
• Y4T4 wave (April 2026): 8 new members debuted simultaneously on Twitch AND YouTube — intentional platform diversification reducing YouTube dependency.
• NIJIFes 2026 at Makuhari Messe (May 14-17, 4 days, 30 performers) — same week as FY2026 earnings release. Largest annual event. Key Q4 Commerce revenue driver.
• Rolling EN auditions: Permanent, always-open auditions launched March 2026. EN rebuild underway.

FY2026 full-year guidance: Revenue ¥54.7-55.6B (+28-30%), OP ¥19.82-20.36B (inventory drag), NI ¥14.22-14.57B. Dividend ¥75/share confirmed.

Thesis breaks if: May 14 results show structural margin compression (not one-time); FY2027 guidance implies <10% revenue growth; Cover Corp achieves revenue parity while growing margins faster.

Supply Chain (Updated)

Risk Flags

⚠️ PB 8.47x: High in absolute terms. However, ANYCOLOR is an asset-light IP/entertainment company with 74% ROE — high PB is structurally justified for capital-light businesses with exceptional returns on equity. Not flagging as a guardrail violation; monitoring.

⚠️ EN Talent Attrition: EN roster ~28 (down from 45+). Permanent auditions launched; rebuilding in progress. Total group talent count is UP YoY — EN decline is not group-level decline.

⚠️ Cover Corp Competitive Gap: Cover Corp market cap ¥90.3B (half of ANYCOLOR ¥183.65B). Cover growing faster on revenue. ANYCOLOR maintains massive margin advantage (40%+ vs Cover ~15%). Watch May 19 Cover earnings for competitive update.

Summary Table

Data Sources

• StockAnalysis (stockanalysis.com) — PE, PB, market cap cross-validation
• Kabutan (kabutan.jp) — JSW current metrics
• Minkabu (minkabu.jp) — Organo current metrics
• IRBank (irbank.net) — Organo historical PBR range
• Nikkei, Bloomberg, Japan Times — nuclear restart confirmations
• ANS, GE Vernova press releases — BWRX-300 supply chain
• Investing.com, TradingView — ANYCOLOR financial data
• GameBiz, Yahoo Finance Japan — ANYCOLOR Q3 results
• The Magic Rain, MoguraVR — ANYCOLOR/Nijisanji talent data

*Research conducted 2026-05-04. All sources dated. Next scheduled evolve: 2026-05-13/14 post-earnings.*